Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995;121(6):364-6.
doi: 10.1007/BF01225689.

Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy

J Q Li  1 , Y Q Zhang, W Z Zhang, Y F Yuan, G H Li
Affiliations
Clinical Trial

Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy

J Q Li et al. J Cancer Res Clin Oncol. 1995.

Abstract

From April 1990 to December 1993, 140 patients were recruited to a randomized study to evaluate transcatheter hepatic arterial chemoembolization (TACE) as an adjuvant therapy for primary liver carcinoma after hepatectomy. This study investigated the principle, techniques and results of TACE. The results showed that the intrahepatic recurrence rate was 48.9% in the patients who underwent radical resection only, but only 21.3% in the patients who also underwent TACE 3-4 weeks after hepatectomy (P < 0.01). The 1-, 2-, 3-, and 4-year survival rates were 72.3%, 52.7%, 35.1%, and 35.1% respectively for the patients who underwent radical resection only, and were 97.9%, 85.5%, 69.5%, and 56.9% for the patients who also underwent TACE 3-4 weeks after radical resection (P < 0.001). The 1-, 2-, 3-, and 4-year survival rates were 38.9%, 0%, 0%, and 0% for the patients who underwent palliative resection only, and were 68.3%, 32.3%, 21.5%, and 21.5% respectively for the patients undergoing TACE 3-4 weeks after palliative hepatectomy (P < 0.001).

PubMed Disclaimer

References

    1. Kojiro M, Nakashima T (1987) Pathology of hepatocellular carcinoma. In: Okuda K (ed) Neoplasms of the liver. Springer, Tokyo Berlin Heidelberg New York, pp 353–104
    1. Li GH, Li JQ (1989) Subclinical primary liver carcinoma. J Surg Oncol 42: 181–183 - PubMed
    1. Nagasue N, Galizia G, Kohno H, et al (1989) Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a restrospective comparison of 138 liver resections. Surgery 106: 81–86 - PubMed
    1. Tang ZY (1985) Subclinical hepatocellular carcinoma historical aspects and general consideration. In: Tang ZY (ed) Subclinical hepatocellular carcinoma. Springer, Berlin Heidelberg New York Tokyo, pp 1–11
    1. Wu MC, Chen H, Zhang XH (1984) Hepatic resection: a 24-year experience (in Chinese). Acta Acad Med Wuhan 6: 379–383

Publication types

LinkOut - more resources